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NEET proteins belong to a highly conserved group of [2Fe–2S] proteins found across 36 
all kingdoms of life. Due to their unique 2Fe-2S cluster structure, they play a key role 37 
in the regulation of many different redox and oxidation processes. In eukaryotes, NEET 38 
proteins are localized to the mitochondria, ER and the membranes connecting these 39 
organelles (MAM), and are involved in the control of multiple processes, ranging from 40 
autophagy and apoptosis to ferroptosis, oxidative stress, cell proliferation, redox control 41 
and iron and iron-sulfur homeostasis. Through their different functions and interactions 42 
with key proteins such as VDAC and Bcl-2, NEET proteins coordinate different 43 
mitochondrial, MAM, ER and cytosolic processes and functions and regulate major 44 
signaling molecules such as calcium and reactive oxygen species. Owing to their central 45 
role in cells, NEET proteins are associated with numerous human maladies including 46 
cancer, metabolic diseases, diabetes, obesity, and neurodegenerative diseases. In recent 47 
years, a new and exciting role for NEET proteins was uncovered, i.e., the regulation of 48 
mitochondrial dynamics and morphology. This new role places NEET proteins at the 49 
forefront of studies into cancer and different metabolic diseases, both associated with 50 
the regulation of mitochondrial dynamics. Here we review recent studies focused on 51 
the evolution, biological role, and structure of NEET proteins, as well as discuss 52 
different studies conducted on NEET protein function using transgenic organisms. We 53 
further discuss the different strategies used in the development of drugs that target 54 
NEET proteins, and link these with the different roles of NEET proteins in cells.  55 
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I. Introduction 56 
 57 
Iron-sulfur (Fe–S) clusters are among the oldest cofactors known to drive electron 58 
transfer reactions [1]. Because of the relatively small energy shifts of Fe–S clusters, 59 
when they transit from their oxidized to reduced forms, Fe–S clusters allow for fast and 60 
ideal electron-transfer conditions [2]. This made Fe-S clusters ubiquitous electron 61 
carriers across the three kingdoms of life. Indeed, Fe-S proteins are involved in many 62 
vital and diverse biochemical reactions, such as photosynthesis, respiration, nitrogen 63 
fixation, iron homeostasis and gene expression [1].  64 
The primary forms of iron-sulfur clusters include [2Fe–2S], [3Fe–4S], and [4Fe–65 
4S] (Fig. 1A). The reduction potential of Fe–S clusters, is dependent on the properties 66 
and structure of their coordinating residues in each specific protein, which in most cases 67 
are thiol side groups of cysteines, with the classical example of ferredoxins [1]. More 68 
rarely, His, Asp, Arg and Thr may coordinate the iron atoms [3]. In particular, histidine 69 
ligands constitute the most common evolutionary choice after cysteines [3], and most 70 
of the Fe–S His-ligand structures are conserved in their respective protein families [3]. 71 
In contrast to cysteine ligands, histidine-coordinated metal ions can have a neutral and 72 
deprotonated state at physiological pH. The former features a higher reduction potential, 73 
whereas the latter exhibits a significantly decreased reduction potential [2, 3]. The 74 
proton-coupled electron transfer (PCET) capabilities of His-ligated Fe–S are pervasive 75 
in redox reactions in complicated biochemical processes [4]. Because the His-ligation 76 
of Fe–S clusters impacts their lability (Fig. 1B), proteins containing His-ligated Fe–S 77 
clusters have been tied to different redox, iron-sulfur cluster biogenesis and cluster-78 
delivery and/or chaperone functions, as well as iron sensing. These proteins include 79 
among others the ISC machinery component IscU, glutaredoxins and NEET proteins 80 
[2, 5].  81 
The first report of a NEET protein, mitoNEET (mNT), was published by Colca et 82 
al. [6]. The protein was predicted to be a zinc-finger protein because of the presence of 83 
the zf-CDGSH zinc-finger domain. However, subsequent biophysical, biochemical and 84 
X-ray structural analyses revealed that mNT contains [2Fe–2S] clusters [5]. The 85 
clusters’ ligands are 3Cys:1His, part of the CDGSH domain (C-X-C-X2-(S/T)-X3-P-86 
X-C-D-G-(S/A/T)-H) [5]. The presence of the histidine ligand leads to a pH-dependent 87 
lability of the clusters [5]. Molecular simulation suggested that the protonation states 88 
of the His-ligand can affect the coordination bond polarity and the H-bond with the Nε 89 
of the His-ligand and thereby control the break of the Fe–His bond [7] (Fig. 1B, red 90 
arrow). This lability allows NEET proteins to transfer their [2Fe–2S] cluster to an apo-91 
acceptor protein [2]. As a result, NEET proteins display unique biochemical properties 92 
associated with their labile [2Fe–2S] clusters [2, 5], which are exploited in iron, reactive 93 




Fig. 1. Structural motifs of common Fe–S clusters and lability of the His-ligated NEET [2Fe–2S] 96 
cluster. (A) The most common coordination structures of Fe–S clusters originated during evolution. (B) 97 
An [2Fe–2S] cluster coordinated by three Cys and one His. Protonation of the His-ligand residue 98 
decreases dramatically its affinity for the [2Fe–2S] cluster [5]. The lability of the cluster under acidic 99 
conditions is used in nature to induce its transfer to apo-receptor proteins [2]. 100 
 101 
NEET proteins are present in all kingdoms of life from archaea to eukaryote, and 102 
only few organisms from the fungi phyla do not contain NEET-encoding genes in their 103 
specialized genomes [8]. The CDGSH domain of NEET proteins most likely appeared 104 
close to the emergence of life around 4 billion years ago (BYA) [8]. Phylogenetic 105 
analysis of the CDGSH domain of NEET proteins revealed that their evolution is linked 106 
with that of the Fer4_19 domain that binds [4Fe–4S] and is a part of many Fe–S proteins 107 
found to be present in the genome of the putative last universal common ancestor 108 
(LUCA) [8]. The fact that no Fer4_19 domain was found in association with the 109 
CDGSH domain in eukaryotes may suggests that the function of this domain could be 110 
different from that existing in prokaryotic organisms (Fig. 2A). NEET proteins can be 111 
divided into two classes: I) NEET proteins with one CDGSH domain per monomer, and 112 
II) NEET proteins with two CDGSH domains per monomer. Phylogenetic studies 113 
suggested that the separation of these two classes of NEET proteins most likely 114 
coincided with the appearance of eukaryotes on earth (~2.3–2.6 BYA) [9].  115 
In vertebrates, the NEET family is composed of three distinct proteins (Fig. 2B): 116 
the membrane-bound mitoNEET (mNT) and nutrient-deprivation autophagy factor-1 117 
(NAF-1) proteins, encoded respectively by the CISD1 and CISD2 genes that belong to 118 
class I NEET proteins; and the soluble mitochondrial inner NEET (MiNT) protein, 119 
encoded by CISD3 that belongs to class II NEET proteins. While mNT and NAF-1 are 120 
homodimeric proteins anchored to the outer membrane of the mitochondria (OMM) [5, 121 
9, 10]. NAF-1 is also localizes to the endoplasmic reticulum (ER) and the membrane 122 
structures connecting the ER to the mitochondria (MAM). In the model plant 123 
Arabidopsis thaliana, only one type of class I NEET proteins was found to be localized 124 
to the outer membranes of the chloroplast, and probably the mitochondria, and was 125 
termed AtNEET (Fig. 2B) [11].  126 
The separation of plant and animal NEET proteins is thought to have occurred 127 
about 1.5 BYA and CISD1 (mNT) and CISD2 (NAF-1) diverged during the emergence 128 
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of vertebrates around 622–768 million years ago (MYA) [8]. The basic structure, 129 
coordination, and labile nature of the [2Fe–2S] clusters of NEET proteins have been 130 
conserved since their initial appearance on Earth [8, 9]. This degree of conservation 131 
highlights the importance of the unique cluster properties of NEET proteins to the role 132 
they play in different organisms, as well as support their involvement in numerous 133 
fundamental cellular processes [2, 5, 12]. 134 
  135 
 136 
Fig. 2. Phylogenetic structural relationships and cluster transfer functions of NEET proteins. (A) 137 
Hypothetical evolutionary time-frame of NEET proteins from the appearance of the CDGSH domain to 138 
the divergence of the latest forms of human NEET proteins; M.E.E. - mitochondrial endo-symbiotic 139 
event, GOE - Great oxygenation event. (B) The two different classes of NEET proteins. Top: The soluble 140 
parts of the membrane-bound human mNT (PDB ID: 2QH7), NAF-1 (4OO7), and the plant AtNEET 141 
(3S2Q). mNT, NAF-1 and AtNEET are homodimeric proteins with one CDGSH domain per monomer 142 
and are representatives of the NEET Class I family. Bottom: The monomeric and soluble human MiNT 143 
protein (6AVJ) that possess two CDGSH domain. (C) The lability of the [2Fe–2S] clusters of NEET 144 
proteins depends on the oxidation and protonation state of their His-ligand residue. When the [2Fe–2S] 145 
cluster is reduced (left) the cluster remains stable even under acidic pH. Oxidation of the Fe and 146 
protonation of the His residue increases the lability of the cluster and allows its transfer to an apo-147 
acceptor-protein (right). 148 
 149 
In this review, we will focus on the role of NEET proteins in the regulating iron, 150 
ROS, and calcium metabolism and homeostasis in eukaryotic organisms, as well as on 151 




II. The role of NEET proteins in protecting the mitochondria from 154 
over accumulation of iron and ROS 155 
 156 
Studies across different organisms ranging from mammalian cells and mice to plants 157 
and C. elegans demonstrated that NEET protein dysfunction leads to disruptions in the 158 
structure and function of specific subcellular organelles such as the mitochondria and 159 
chloroplast [5, 11, 13, 14], accompanied by alterations in subcellular levels of iron and 160 
ROS in these organelles. These studies highlighted the key role NEET proteins play in 161 
regulating iron and ROS levels [2, 5, 12] in mammalian cells (discussed below), plants 162 
and C. elegans (section VII). 163 
In eukaryotes, mitochondria provide a key source of ATP, as well as serve as the 164 
main site for iron-sulfur [2Fe–2S] cluster biogenesis, heme synthesis, and fatty acids 165 
metabolism [1, 15]. In an effort to understand the mechanism of action of 166 
thiazolidinediones (TZDs), Colca’s group investigated new mitochondrial binding 167 
targets of the anti-diabetes type II compound pioglitazone - PGZ [6]. Their study 168 
identified mNT, the first NEET protein that was found to bind PGZ. A successive study 169 
identified a total of three NEET proteins, mNT, NAF-1 and MiNT encoded by CISD1, 170 
CISD2 and CISD3 genes, respectively in mammalian cells [5]. mNT was found to be 171 
exclusively localized on the OMM, where each of its monomers is anchored by a single 172 
α-helix trans-membrane domain with the main part of the protein facing the cytosol [2, 173 
5]. NAF-1 was found to be localized to the OMM, the ER membranes and the 174 
membranes that connect the mitochondria to the ER (MAM) [5]. The monomeric 175 
globular MiNT protein was shown to be localized inside the mitochondria [5] (Fig. 3).  176 
Fig. 3. NEET proteins localization in mammalian cells. mNT is localized to the outer mitochondrial 177 
membrane (OMM) [5], NAF-1 is localized to the OMM as well as to the ER membranes and the 178 
mitochondrial associated membranes (MAM) [5], whereas MiNT is localized inside of the mitochondria 179 
[5]. 180 
 181 
A recent study revealed that mNT and NAF-1 interact and that mNT can transfer 182 
its [2Fe–2S] to NAF-1 (but not vice-versa) [16]. In addition to interacting with NAF-1, 183 
mNT was also recently shown to have an interaction with the outer-mitochondrial 184 
7 
 
membrane protein voltage-dependent anion channel (VDAC1) [17, 18].  185 
 186 
IIa. NEET proteins role in ROS hemostasis, respiration (via Complex 1), ATP 187 
production, redox regulation, and nitric oxide and fatty acids metabolism 188 
 189 
Two hypotheses regarding the functional role of NEET proteins were proposed based 190 
on NEET proteins’ unique properties of having redox active and labile [2Fe–2S] 191 
clusters [5]: 1. A role for NEET proteins in electron transfer reactions, based on the 192 
interactions of mNT with mitochondrial proteins such as the mitochondrial outer 193 
membrane import complex protein 1 (MTX1), glutathione reductase, glutamate 194 
dehydrogenase 1 [19], and reduced flavin mononucleotide (FMNH2) [20]; and 2. A role 195 
for NEET proteins in iron-sulfur cluster transfer based on the in vitro ability of all three 196 
NEET proteins to transfer their clusters to apo-acceptor proteins such as apo-ferredoxin 197 
[2, 5]. In addition, mNT was proposed to play a novel role in a pathway that repairs the 198 
cluster of the cytosolic iron regulatory protein1 (IRP1) in mammalian cells [21]. mNT 199 
and/or NAF-1 were also shown to transfer their clusters to anamorsin, a protein required 200 
for iron sulfur cluster assembly in the cytosol [22]. NEET proteins were further 201 
suggested to have a sensing function and to balance and protect cells from 202 
environmental changes such as nutrient deprivation, oxidative stress, or iron overload, 203 
triggering different cellular mechanisms such as autophagy, apoptosis and ferroptosis 204 
[12]. The sensing mechanism, which controls the activity of NEET proteins in response 205 
to redox signals via changes in the redox state of NEET proteins’ clusters, can also 206 
impact their role as electron or [2Fe–2S] cluster transfer proteins.  207 
Recent studies, using a wide array of genetic and biochemical tools, revealed that 208 
NEET proteins are involved in many other essential biological processes, such as 209 
energy metabolism via OXPHOS for ATP production [5] and β-oxidation of lipids [5, 210 
23]. NEET proteins also play a major role in iron-ROS homeostasis [2, 5, 10] and Fe–211 
S biogenesis [10]. The latter implicates them in the regulation of inflammation [5], 212 
autophagy and apoptosis [5, 11, 24], neuronal development [5], and longevity [25, 26]. 213 
In particular, mNT is involved in energy metabolism in mitochondria affecting 214 
OXPHOS and lipid metabolism via binding to components in complex I or other 215 
partners such as GDH1 [5, 23], in the regulation of iron and ROS homeostasis via 216 
transferring clusters to possible acceptor proteins such as ferredoxin, iron regulatory 217 
protein 1 and anamorsin [12, 21, 22], in β-cell insulin secretion [27], in cell proliferation 218 
of human breast cancer [12] and in lipid accumulation in adipocytes [23]. Suppression 219 
of NEET protein expression may increase ADP/ATP ratio, along with NAD+/NADH 220 
ratio [28]. When mNT expression is suppressed, disruptions in mitochondrial 221 
respiration occur and this is associated with decreased mitochondrial volume and 222 
function [29]. In contrast to mNT, NAF-1 was shown to be primarily involved in 223 
regulating intracellular calcium homeostasis [30], in the maintenance of mitochondrial 224 
integrity and in controlling ER functions and lifespan [25] as well as potentially playing 225 
a role in the inflammatory response [31]. MiNT is the least characterized among NEET 226 
proteins. It resides inside the mitochondrial matrix and was shown to have a role in 227 
regulating mitochondrial iron and reactive oxygen homeostasis [10]. MiNT can also 228 
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bind NO (nitric oxide) when its [2Fe–2S] clusters are reduced while the other two 229 
human NEET proteins, mNT and NAF-1, fail to bind NO. But interestingly a single 230 
amino acid mutation, (D96V in mNT, or D123V in NAF-1) facilitates the binding of 231 
NO to the [2Fe–2S] cluster indicating that subtle changes to these proteins may switch 232 
their ability to bind NO, and thereby facilitate signaling in cells and modulation of 233 
mitochondrial function through NO signaling [32]. Binding of nitric oxide can inhibit 234 
the electron transfer activity of MiNT [2Fe–2S] clusters suggesting that mitochondrial 235 
NEET proteins may play a novel role in energy metabolism in cells, and that nitric oxide 236 
may regulate the electron transfer activity of NEET proteins and modulate energy 237 
metabolism in mitochondria [33]. MiNT may also be involved in protein-protein 238 
interaction(s) inside the mitochondrial matrix. Potential functional partners of MiNT 239 
include multiple components of the respiratory complex I, ribosomal RNA binding 240 
proteins, glutathione-S transferase and many other proteins in Fe–S biogenesis [10]. In 241 
different cellular models, low expression levels of NEET proteins commonly showed a 242 
decrease in mitochondrial membrane potential (MMP) [5, 34, 35], an increase in the 243 
accumulation of mitochondrial iron and ROS, and an increase in autophagy and 244 
apoptosis [10, 12]. All of these mitochondrial dysfunctions were mitigated by iron 245 
chelators such as Deferiprone (DFP) or by re-expression of the suppressed NEET 246 
proteins to normal levels (personal communication). Similar to mNT and NAF-1, MiNT 247 
could also have a key role, albeit functioning from within the mitochondria, in 248 
regulating iron and ROS homeostasis.  249 
An accumulating lines of evidence suggests that NEET proteins have a balancing 250 
and/or protecting role from over-accumulation of iron and ROS in intra-cellular 251 
organelles such as mitochondria. Recent studies demonstrated that NEET proteins have 252 
a protecting role in human melanoma cells by alleviating mitochondrial dysfunctions 253 
and apoptosis [36]; in liver cells they can antagonize mitochondrial lipid peroxidation 254 
and inhibit ferroptosis [37]; and in an Alzheimer’s disease (AD) mouse model they 255 
could be involved in attenuating amyloid β-mediated mitochondrial damage and loss of 256 
neurons [38]. Recently, mNT and NAF-1 were shown to cooperate in the control of iron 257 
and ROS homeostasis in mitochondria [12], and the link between these proteins, as 258 
balancing factors for iron, Fe–S, and ROS homeostasis, was confirmed by genetically 259 
manipulating their levels. Furthermore, it appears that MiNT is similarly involved in 260 
this balancing act (personal communication). Through their role in regulating iron and 261 
ROS, NEET proteins could therefore regulate cellular proliferation, apoptosis and 262 







Fig. 4. NEET proteins participation in different mitochondrial functions. mNT participates in 268 
several mitochondrial metabolic functions, as well as in energy transduction through interactions 269 
with respiratory complex I, glutathione-S transferase, fatty acids metabolism and Fe–S biogenesis. 270 
MiNT is known to regulate mitochondrial iron and reactive oxygen homeostasis, electron transfer 271 
and NO hemostasis.  272 
 273 
 274 
IIb. Mitochondrial dynamics and NEET proteins 275 
  276 
Control of mitochondrial dynamics through processes such as fusion, fission and 277 
degradation, highlights the high plasticity needed for the regulation of mitochondrial 278 
hemostasis, metabolism and function [39]. Mitochondrial adaptations through 279 
morphological changes - fragmentation or elongation, depend on nutrient availability, 280 
as well as ATP production capacity and demand in response to changes in 281 
environmental, metabolic or developmental conditions [40]. Mitochondrial dynamics 282 
is a highly controlled process. Fusion requires three large GTP-hydrolyzing enzymes. 283 
The first two, mitofusin 1 and mitofusin 2 (MFN1/2) are located on the outer 284 
mitochondrial membrane and are responsible for the fusion of this membrane. The third 285 
enzyme, called Optic Atrophy 1 (OPA1), is localized to the inner mitochondrial 286 
membrane. It is responsible for the fusion of the inner mitochondrial membrane [39, 287 
41]. Mitochondrial fission uses the so-called GTP-hydrolyzing enzyme dynamin-288 
related protein 1 (DRP1). This protein is being recruited from the cytosol onto the 289 
mitochondrial surface to induce fission [39, 41]. 290 
ER/mitochondria cross talk regulates ER stress signaling, the unfolded protein 291 
response (UPR) and iron homeostasis. The mitochondrial associated membranes 292 
(MAM) interface plays a key role for pathological abnormalities such as diabetes and 293 
neurodegenerative diseases [28, 41]. It was suggested that mitochondrial dynamic 294 
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abnormalities impact the entire inter-organelle communication network of cells, in turn 295 
impacting overall cellular survival and bioenergetics [40]. Mitochondria play a major 296 
role in iron metabolism through iron-sulfur Fe–S cluster and heme biosynthesis 297 
processes, controlled by several regulatory proteins, among which are NEET proteins 298 
[2, 5, 12, 15]. Mitochondrial iron hemostasis is considered a regulator of mitochondrial 299 
morphology [42]. Disrupting the expression of any of the three human NEET proteins 300 
i.e., mNT, NAF-1 or MiNT, was shown to result in the over accumulation of 301 
mitochondrial labile iron levels [2, 5, 10, 12]. Increased mitochondrial iron, or cellular 302 
iron in general, causes disturbances in mitochondrial dynamic, and will interfere with 303 
the balance between mitochondrial fission and fusion [40], through increased 304 
production of ROS and other radicals [43]. Decrease in the expression of mNT or NAF-305 
1 causes abnormalities in mitochondrial membrane potential (MMP) [5, 12, 35], and 306 
loss of mNT was shown to cause intra-mitochondrial junctions and network contacts 307 
abnormalities (Fig. 5) [29].  308 
 309 
Fig. 5. Lowering the expression of NEET proteins results in mitochondrial fission. NEET proteins 310 
are involved in controlling iron and oxidative stress. When the mNT or NAF-1 expression is knocked 311 
down (KD) or knocked out (KO), an increase in mLI (represented as red circle) and ROS (represented 312 
as yellow stars) is observed. These stimulate fission of the mitochondria probably mediated by the DRP1 313 
protein [43]. Mitochondrial images were adapted from Holt, et. al. 2016 [34]. 314 
 315 
Similarly, decrease in NAF-1 levels is accompanied by disruptions in 316 
mitochondrial morphology, including fission, fusion, inner membrane translocation, 317 
outer membrane translocation, mitochondrial protein import and membrane 318 
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polarization and potential [35]. In addition, decreased expression of MiNT results in 319 
disturbances in MMP [10]. The increase in mitochondrial labile iron (mLI) caused by a 320 
deficiency in any of the NEET proteins could therefore disrupt mitochondrial dynamics 321 
favoring fission and triggering mitophagy and ferroptosis in cell [40, 43]. This 322 
disturbance could also be linked to disruptions in Ca2+ signaling caused by NEET 323 
abnormalities (detailed in the section below) with the latter causing mitochondrial 324 
fragmentation and fission by DRP1 [43]. However, the findings that iron chelators that 325 
correct the NEET-derived abnormalities in mLI [12], can lead to mitochondrial 326 
elongation by decreasing the expression of mitochondrial fission modulators of DRP1 327 
[40, 44], suggest that the effect of iron on these processes is more pronounced than that 328 
of calcium.  329 
Numerous proteins found to impact or control mitochondrial dynamics are present 330 
at the MAM region, side-by-side with mNT and NAF-1, and many of these proteins 331 
were shown to physically, or functionally, interact with mNT and NAF-1 [12, 17, 28, 332 
45, 46]. The main proteins controlling MAM integrity found to be affected by NEET 333 
protein function include inositol 1,4,5-trisphosphate receptor (IP3R) and voltage-334 
dependent anion channel (VDAC), and these two proteins communicate with each other 335 
via the HSC70 chaperon family protein GRP75 [41]. In addition to the different roles 336 
of these proteins linking Ca2+ signaling to the tethering of MAM and the formation of 337 
MAM contact sites, their interaction with NEET proteins such as mNT and NAF-1 338 
could expand the control of these processes to include responses to changes in redox, 339 
ROS, iron and Fe–S metabolism. NEET proteins could therefore serve as important 340 
links between these processes and mitochondrial dynamics through interactions with 341 
different proteins found at the MAM [41]. Altogether, NEET proteins may play an 342 
important physiological role in controlling the mitochondria, ER and MAM hemostasis 343 
and structure [29, 35, 41], linking mitochondrial iron/ Ca2+ imbalanced and Fe–S 344 
hemostasis with mitochondrial ROS production [37] and mitochondrial dynamic 345 
morphological changes.  346 
 347 
 348 
III. NEET proteins constitute an important link between calcium 349 
signaling and iron metabolism 350 
 351 
Interactions between the mitochondria and the ER are critical for maintaining normal 352 
cellular functions. These interactions primarily occur at the contact sites between the 353 
two organelles known as the ER- mitochondrial associated membrane (MAM) network 354 
[31]. The MAM network is believed to be the site in which the ER and mitochondria 355 
cooperate to exchange signals and regulate proper cellular functions including Ca2+ 356 
signaling, lipid metabolism, autophagy, cell survival and cell death [41]. Maintaining 357 
optimal distance between the mitochondria and the ER through numerous regulatory 358 
proteins that reside in the MAM secures proper Ca2+ transport and signaling between 359 
these two organelles [47]. Mitochondria, ER and MAM integrity is therefore important 360 
for preventing abnormalities that may cause sever diseases such as neurodegenerative 361 
diseases, diabetes, inflammation, and cancer [31]. Under normal physiological 362 
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conditions, iron is known to regulate ROS generation that alters normal Ca2+-dependent 363 
signaling pathways. Yet, excessive iron levels which promote oxidative stress lead to 364 
disturbances in Ca2+ signals, which among other downstream effects induce damage to 365 
mitochondrial function [48]. On the other hand, increasing mitochondrial Ca2+ to non-366 
physiological levels also causes mitochondrial dysfunction and loss of iron hemostasis. 367 
This highly controlled self-sustained cycle of iron and Ca2+ is essential for the control 368 
of mitochondrial health and the regulation of key cellular functions [48].  369 
While NAF-1 was shown to play a regulatory role in maintaining mLI, Fe–S and 370 
mROS hemostasis [2, 5, 12, 49], and could impact Ca2+ levels through altering iron and 371 
ROS, NAF-1 was also shown to be a more direct regulator of Ca2+ hemostasis between 372 
the mitochondria and the ER [5, 50, 51]. It is thought that this control is maintained by 373 
the interactions of NAF-1 with different Ca2+ associated proteins such as IP3R [52], as 374 
well as its effect on the unfolded protein response (UPR) related to Ca2+ regulation and 375 
ER stress [28, 41]. NAF-1 is known to interact with Bcl-2 during autophagy [45, 46], 376 
an interaction controlled by the absence or presence of its [2Fe–2S] clusters [5], and 377 
the process of autophagy is thought to be linked to Bcl-2-NAF-1 regulated ER-Ca2+ 378 
stores [2, 5]. Suppression of NAF-1 in knock-out cellular models, disrupts cytosolic 379 
and ER-stores of Ca2+ suggesting a role for NAF-1 and Bcl-2 in the regulation of 380 
autophagy upon Ca2+ release from the ER (Fig. 6) [52-54].  381 
NAF-1 KO models, have shown alterations in Ca2+ concentration at the ER lumen 382 
that lead to increases in ER stress resulting in the activation of UPR [28]. Moreover, 383 
NAF-1 was shown to be a part of the IP3R macro-complex that is required for 384 
controlling ER Ca2+ stores and signaling through the MAM [45, 46, 53, 54]. IP3R is 385 
known to mediate ER Ca2+ efflux through its redox-sensitive cysteines [28]. KO models 386 
of NAF-1 also show cellular dysregulation of Ca2+ that results in lower basal levels of 387 
cytosolic Ca2+, depletion of the ER Ca2+ stores and dramatic increases of mitochondrial 388 
Ca2+ load [28]. The latter suggested the involvement of proteins mediating ER Ca2+ 389 
influx activity, such as the ER sarco-endoplasmic reticulum Ca2+ ATPase (SERCA2) 390 
protein, which takes up Ca2+ from the cytosol and delivers it to the ER lumen [28, 51, 391 
52]. The KO models of NAF-1 also showed alteration in mitochondrial function and 392 
structure that are further affected by increased mitochondrial Ca2+ levels [28, 51]. 393 
Suppression of NAF-1 was also reported to impair intracellular Ca2+ hemostasis, 394 
through the SERCA2 protein especially SERCA2b isoform in hepatocytes [51], 395 
SERCA 2a in the heart [55], or SERCA1 in skeletal muscle [56]. It was suggested that 396 
NAF-1 absence altered the redox status of the cell and increased oxidative 397 
modifications and glutathionylation of SERCA proteins, impairing Ca2+ pumping 398 
activity from the ER, resulting in ER stress and mitochondrial abnormalities [51-53, 399 
55-57]. These abnormalities were shown to be related to aging, in which the activity of 400 
SERCA is significantly decreased, especially when the NAF-1 protein is absent (Fig. 6) 401 
[55, 56].  402 
NAF-1 was also shown to interact at the MAM area with GTPase of immune-403 
associated protein 5 (Gimap5). This interaction suggested that both proteins are 404 
essential for mitochondrial integrity and the buffering capacity of Ca2+ levels through 405 
the control of mitochondrial Ca2+ uptake that was shown to be important in the 406 
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maintenance of intracellular Ca2+ hemostasis in cells [30, 35, 52, 54]. On the other hand, 407 
deficiency in NAF-1 that increases cytosolic Ca2+ levels, affecting Ca2+-dependent 408 
phosphatase signaling pathways as a secondary response, is known to involve 409 
calcineurin and affects different cellular functions including adipogenesis in adipose 410 
tissues, as well as the regulation of glucose hemostasis [30, 52]. In another study of 411 
Ca2+ hemostasis, NAF-1 was found to be involved in the negative regulation of Calpin2, 412 
a Ca2+-dependent protease, known to be activated by high cytosolic Ca2+. When NAF-413 
1 is absent from cells this process could cause hyperactivity of Calpin2 to different 414 
signals and the activation of cell death (Fig. 6) [58]. 415 
An important recent study further identified a redox-sensitive binding interaction 416 
between mNT and the voltage-dependent anion channel 1 (VDAC1) protein complex, 417 
a crucial crosstalk point between the mitochondria and the cytosol that regulates the 418 
transfer of ions, including Ca2+, different metabolites and ROS (Fig. 6) [17, 59]. The 419 
ability of the redox sensitive [2Fe–2S] cluster protein mNT to bind and block VDAC 420 
in response to changes in cellular redox states highlights a new and exciting way in 421 
which NEET proteins could regulate mitochondria-to-cytosol calcium signals in 422 
response to changes in redox, iron, ROS and [Fe–S] levels [17]. This regulation is 423 
thought to play a hemostatic role in protecting mitochondria, ER and the MAM [17].  424 
 425 
Fig. 6. NEET proteins involvement in calcium signaling at the mitochondrial ER and MAM 426 
junction. The role of NEET proteins in the regulation of Ca2+ and iron hemostasis at the mitochondria-427 
ER-MAM interface is depicted. The complementary role of mNT and NAF-1 in [2Fe–2S] cluster transfer 428 
and interactions with different ER and mitochondrial proteins (SERCA, IP3R, Gimap5 and VDAC) that 429 
regulate proper Ca2+ signaling through the MAM is shown in the model. mNT could also contribute to 430 
[2Fe–2S] translocation from the mitochondria via VDAC. GRP75 regulates the interaction between IP3R 431 
and VDAC that plays a role in the integrity of the MAM. mNT and NAF-1 bind with AGBE, an iron 432 
regulator that ensures the function of the holo-IRP. mNT also has a role in the reactivation of holo-IRP. 433 
 434 
VDAC may have a further role in the transferring of [2Fe–2S] clusters from inside 435 
the mitochondria to mNT [17]. In addition to the mNT-VDAC interaction, a C-terminal 436 
truncated version of VDAC interacts with NAF-1 to confer resistance to cellular 437 
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apoptosis [18]. Moreover, mNT and/or NAF-1 binds specifically with 1,4-Alpha-438 
Glycogen Branching Enzyme (AGBE) that is known as a regulator for iron hemostasis, 439 
to ensure that holo-IRP1 remains functional and can enter to the nucleus [60].  440 
 441 
 442 
IV. Involvement of NEET proteins in metabolic and genetic diseases  443 
 444 
IVa. NEET proteins and Diabetes 445 
 446 
Diabetes is a worldwide epidemic with significant social and economical burdens [61]. 447 
It is an important public health challenge, and considered as a leading cause for 448 
morbidity and mortality worldwide [62]. Diabetes is a group of metabolic diseases 449 
characterized by hyperglycemia due to a defect in insulin secretion, insulin sensitivity 450 
or both [63]. These pathogenic defects range from autoimmune-related destruction of 451 
pancreatic β-cells causing insulin deficiency to abnormalities which cause resistance to 452 
insulin uptake and action [63]. Several different factors are thought to be associated 453 
with the development and progression of diabetes, among them is oxidative stress. 454 
Diabetes is usually accompanied by the over accumulation of free radicals and/or 455 
impaired antioxidant mechanism [63, 64]. Iron hemostasis was also shown to play a 456 
key role in diabetes and other metabolic diseases [65], and it is thought that disturbances 457 
in iron homeostasis may affect glucose metabolism, insulin sensitivity and insulin 458 
secretion, but the exact mechanism of iron-induced diabetes is yet to be determined 459 
[64]. Systemic metabolic disorders such as diabetes and neurodegeneration were further 460 
linked to disturbances in mitochondrial function resulting from iron and oxidative stress 461 
derived processes [66].  462 
NEET proteins are known to participate in iron, [Fe–S], Ca2+ and ROS hemostasis 463 
in mitochondria [2, 5, 12], and the first NEET protein identified, mNT was recognized 464 
as a novel mitochondria protein that cross-linked to the anti-diabetic drug 465 
Thiazolidinedione (TZD), used in the treatment for Type-2-Diabetes (T2D). TZD is 466 
known as a direct activator of peroxisome proliferator activated receptor-γ (PPAR-γ) 467 
[6]. TZD treatment leads to improvement in insulin action and sensitivity in all tissues 468 
[6]. TZD was also shown to stabilize the [2Fe–2S] clusters of NEET proteins, 469 
preventing their loss or their transfer of their [2Fe–2S] clusters to apo-acceptor proteins 470 
[5, 67]. NEET proteins were confirmed to have a role in the pathology of diseases 471 
related to mitochondrial dysfunction, including diabetes [5]. It is thought that 472 
overexpression of mNT preserves insulin sensitivity in adipose tissue (see below), 473 
whereas decrease in mNT expression leads to increased oxidative stress and glucose 474 
intolerance [23]. Mitochondrial dynamics is also affected by oxidative stress causing 475 
dysfunctions in insulin secretion or action [68]. Mitochondrial damage and dysfunction 476 
are important defects associated with a decrease in the level or function of NEET 477 
proteins [5, 10, 12, 34]; the latter were related to decreased insulin production by the 478 
pancreas in type 1 diabetes [49]. NEET proteins were shown to be powerful factors in 479 
mitochondrial metabolism in pancreatic cells, and to affect glucose hemostasis in type 480 
1 and type 2 diabetes [23, 69]. Increasing the activity of NEET proteins is crucial to the 481 
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maintenance of fat reserves and energy hemostasis, along with resistance to diabetes 482 
[23]. While reduction in the expression of NEET proteins causes impaired glucose 483 
metabolism and diabetes [23, 68]. Decrease in NEET protein expression causes an 484 
increase in mitochondrial ROS and oxidative stress, due to the increase of mLI [12], 485 
and disruption in mLI and ROS affect mitochondrial dynamics and function [5, 10]. 486 
Induction of mNT in β-pancreatic cells, responsible for glucose stimulated insulin 487 
secretion, causes hyperglycemia and glucose intolerance due to the activation of Parkin-488 
dependent mitophagy [27]. While mNT induction in pancreatic α-cells, which play an 489 
important role controlling hyperglycemia by hyperglucagonemia, leads to 490 
hypoglycemia and hyper secretion of glucose induced insulin [27]. However, 491 
decreasing the expression of mNT in pancreatic α- and β-cells causes reduced 492 
mitochondrial function in α-cells, while protecting β-cells viability and mass [27]. The 493 
differential role displayed by mNT in pancreatic α- and β-cells, reveals a critical 494 
mechanism by which compromised mitochondrial function alters β-cell insulin 495 
secretion and α-cell glucagon production, preserving insulin sensitivity under metabolic 496 
challenges [27]. 497 
Mutations in NAF-1, the causative agent of the rare genetic disease Wolfram 498 
Syndrome Type 2 (WFS-T2) described below, result in the development of diabetic 499 
features that mimic type 1 diabetes [70]. Absence of NAF-1 was shown to be 500 
responsible for the loss of β-pancreatic cells function [49, 69]. In WFS-T2 the 501 
destruction of pancreatic β-cells and their associated insulin secretion was related to the 502 
unique localization of NAF-1 to the MAM (detailed above) [5, 41]. Adipose-specific 503 
loss of NAF-1 is also associated with a reduction in ER-mitochondrial interactions, 504 
mitochondrial dysfunction and altered insulin signaling in adipose tissue [71, 72]. The 505 
critical roles NAF-1 plays in mitochondria, MAM and ER hemostasis [25, 28, 41, 49], 506 
as well as in the regulation of autophagy [5, 45, 73], apoptosis [24, 34] and ferroptosis 507 
[12, 74], makes NAF-1 a crucial player in pancreatic β-cell integrity. NAF-1 absence 508 
could therefore cause disruptions and increased program cell death (PCD) of pancreatic 509 
β-cells associated with type 1 or 2 diabetes [49, 50, 69, 70, 75, 76]. 510 
 511 
IVb. NEET proteins and obesity 512 
 513 
Obesity is a worldwide disease associated with type 2 diabetes and metabolic disorders 514 
[77]. Obesity is primarily characterized by an increase in circulating fatty acids, and 515 
accumulation of triacylglycerol, that contributes to mitochondrial alterations, increased 516 
lipotoxicity, elevated oxidative stress and impaired energy substrate metabolism and 517 
oxidative phosphorylation (OXPOX), which is related to diabetes [78]. Obesity is a 518 
multifactorial disease that is influenced by diet and results from mitochondrial disorders 519 
[77]. Mitochondria manage the production of energy by controlling the fate of lipids 520 
through β-oxidation or storage in adipose tissue. These mechanisms require that 521 
mitochondrial energy production will be coordinated with the tri-carboxylic acid cycle 522 
and the electron transport chain (ETC). Failure in controlling these highly coordinated 523 
functions was shown to be associated with obesity and type 2 diabetes [77]. NEET 524 
proteins were shown to be essential for the maintenance of mitochondrial energy 525 
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production and fatty acid metabolism. An ob/ob mice model, with a genetic background 526 
that induces an expansion of adipocyte tissues leading to an obesity phenotype, was 527 
shown to have a diminished expression of mNT [23]. In the same model, the 528 
overexpression of mNT was found to decrease β-oxidation rates of lipids and to exhibit 529 
higher lipid accumulation due to an increase in adiponectin production [23]. Lower 530 
rates of β-oxidation were attributed to lower mitochondrial iron content that affected 531 
the ETC resulting in a decrease in ROS production [23]. Interestingly, this observed 532 
phenotype was accompanied by persistent insulin sensitivity. In contrast, when the 533 
expression level of mNT was decreased, opposite phenotypes were observed including 534 
increased oxidative stress and diminished glucose tolerance [23]. The observed lower 535 
insulin sensitivity may result from increased mitochondrial ROS production when the 536 
level of mNT expression is decreased [12]. Treatment of ob/ob mice with antioxidants 537 
lowered lipid oxidation [23], suggesting that lowering oxidative stress could be a 538 
therapeutic approach for these disease, highlighting the potential importance of mNT 539 
expression and function in the development of obesity and associate metabolic diseases. 540 
A study of the transcriptome signature of mice white adipocyte tissue (WAT), in which 541 
mNT was overexpressed, supported the idea that mNT impacts the management of 542 
inflammatory mechanisms and mitochondrial iron and ROS homeostasis associated 543 
with obesity and metabolic diseases [79]. 544 
The expression of mNT is increased during the differentiation of human adipocytes 545 
and is maintained in these tissues [80]. Interestingly, similar to the observations made 546 
with the ob/ob mice model [23], mNT expression was downregulated in the 547 
subcutaneous (SAT) and visceral (VAT) adipose tissues of human patients with obesity 548 
phenotype [80]. The expression level of mNT was also correlated with an adipogenesis 549 
expression pattern in the VAT but not in the SAT [80]. In patients with morbid obesity, 550 
mNT expression was positively correlated with insulin sensitivity and the expression 551 
of the protein Sirtuin 1 (SIRT1) in both types of adipocyte tissues [80]. SIRT1 552 
deacetylase was shown to be related to mitochondrial biogenesis and the browning of 553 
white adipocyte tissues [81]. Expression of SIRT1 was shown to have a beneficial effect 554 
on the physiology of adipocyte tissues. In contrast, lower expression of this protein is 555 
associated with the development of obesity and associated metabolic diseases [82]. 556 
Moreover, the expression of mNT was also positively correlated with transcripts 557 
involved in iron homeostasis [80]. Another protein, ISCA2 which is involved in [Fe–S] 558 
cluster biogenesis [1], was shown to positively correlate with the expression of mNT. 559 
These findings support the idea that NEET proteins are an important factor in this 560 
biogenesis mechanisms [5].  561 
Development of obesity, and related metabolic diseases, appear to be linked with 562 
the expression of NEET proteins (mainly mNT), and their unique [2Fe–2S] cluster 563 
lability properties. Loss of insulin sensitivity (type 2 diabetes) is correlated with the 564 
development of obesity [77] and was shown to depend on the expression level of mNT, 565 
not only in mice models [23], but also in humans [80]. The function of NEET proteins 566 
in mitochondrial morpho-dynamism (see above), could therefore affect mitochondrial 567 
dysfunction associated with different metabolic diseases such as obesity and type 2 568 
diabetes. NEET proteins may therefore be novel targets for drug development and 569 
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treatment of metabolic abnormalities including, obesity and type 1 and type 2 diabetes 570 
[49, 83]. 571 
 572 
IVc. NAF-1 and Wolfram Syndrome Type 2 (WFS-T2) 573 
 574 
The first genetic study of WFS-T2 syndrome was reported in 2007. This study, 575 
conducted on three families from Jordan, identified a single missense mutation at 576 
nucleotide 109 that converts GC leading to an amino acid change from Glutamic acid 577 
to Glutamine (E87Q) (Fig. 7) [69]. Moreover, haplotype analysis of these patients 578 
revealed a common haplotype with similar markers in the linked region of this gene, 579 
which indicates a common ancestor founder for this mutation [69]. In WFS-T2, the 580 
mutated base (G109C) is located six bases away from the Intron-Exon junction, at the 581 
5’ end of Exon 2. Moreover, this missense mutation disrupts mRNA splicing, leading 582 
to skipping of Exon 2 in the final transcript [69]. This change is considered to be a 583 
disruption of an exonic splice enhancer (ESE) that affects the accurate splicing of the 584 
mRNA for this gene [69] leading to a splice-site mutation [69]. In addition, the (G109C) 585 
mutation also leads to a frameshift in exon 3, which creates a premature stop codon. 586 
The resulting spliced mRNA product encodes for a 34 amino acids peptide (26 encoded 587 
from exon 1 and 8 amino acids from Exon 3 [69]. At the protein level, this WFS-T2-588 
mRNA encodes a NAF-1 protein that comprises of only 25% of native NAF-1; i.e. an 589 
elimination of 75% of the wild type NAF-1 protein occurs [5, 69]. The eliminated 590 
protein parts include the NAF-1 transmembrane α-helix domain, which is the leader 591 
sequence of the entire NAF-1 which targets the protein to the mitochondria, ER, and 592 
MAM membranes [5, 69]. Also, all soluble parts of NAF-1, including the β-cap domain 593 
and the cluster-binding domain with its [2Fe–2S] clusters, are missing in WFS-T2 594 
patients [5, 69]. The amino acids that remain comprise mainly of the inner organelle 595 
part of NAF-1 that cannot penetrate the organelles due to the absence of a leader 596 
sequence in the truncated WFS-T2-NAF-1 protein [2]. Hence, it is reasonable to assume 597 
that this short version of NAF-1 is degraded by cytoplasmic proteases (Fig. 7) [84]. 598 
In 2014 a first case of European Caucasian WFS-T2 patient was reported. A genetic 599 
study for this patient revealed a novel homozygous deletion of Exon 2, with a proximal 600 
breakpoint predicted deletion size of about 2,050 base pairs, spanning from Intron 2 to 601 
Intron 3 [75]. Exon 2 of the patient was completely absent, while exon 1 and 3 were 602 
present [75]. Altogether, the novel homozygous deletion of Exon 2 affecting NAF-1 603 
protein, due to the elimination of amino acids from position 102 to 106 of the 604 
polypeptide, that are in the [2Fe–2S] domain region [2, 75].  605 
In 2015 two Italian siblings were also diagnosed with WFS-T2. Their mutation was 606 
a homozygous substitution in a conserved site of Guanine nucleotide with adenine 607 
residue; at the position 103+1 (G103A) in the donor splice site of Intron 1 [76]. This 608 
mutation impaired mRNA splicing pattern, producing multiple splice variants, resulting 609 
in the retaining of a large segment of Intron 1. Consequently producing a skipping effect 610 
causing whole or partial absence of Exon 1 in the transcripts of the patients [76, 84, 85]. 611 
By investigating the cells with the (G103A) mutation, it was found that the mRNA 612 
levels of CISD2 were decreased by almost 99-100% in homozygote cells compared to 613 
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normal cells. Heterozygotes cells showed 64-65% decrease in NAF-1 mRNA levels 614 
compared to control normal cells. This analysis demonstrated the high instability of the 615 
mutated mRNA [84, 85]. Using a polyclonal antibody against the C-terminus of NAF-616 
1, NAF-1 was confirmed to be completely absent in patient cells, whereas its expression 617 
was approximately decreased by 50% in the heterozygous parents compared to healthy 618 
controls [84]. 619 
Another case of WFS-T2 was reported in a Moroccan patient in 2017. CISD2 gene 620 
sequencing revealed a novel homozygous variant, in which Adenine is substituted with 621 
Guanine at position 215 in Exon 2 (A215G). This missense variant changed a highly 622 
conserved Asparagine amino acid at the position 72 into a Serine (N72S), which is 623 
present within a random coil region of the cluster binding domain of the NAF-1 protein 624 
[2, 50]. Analyzing mRNA splicing revealed no abnormal expression or mis-splicing 625 
effect. In addition, protein expression levels appeared normal [50]. At the cellular level, 626 
ER and mitochondria structure and function were impacted due to the dysfunctional 627 
protein caused by the mutation, which highlight the important regulatory part of the 628 
affected NAF-1 protein domain in these cells. The expression of a non-fully functional 629 
NAF-1 variant in Fibroblast cells of these patients, caused an increase contact between 630 
the mitochondria and the ER as well as increased elongation of the mitochondria, 631 
suggesting that disrupting NAF-1 function can trigger a process of stress-induced 632 
mitochondrial hyper-fusion [50]. A full mechanistic explanation for the impact of this 633 
mutation on NAF-1 function awaits however further investigation [50]. 634 
Two additional unrelated new cases of WFS-T2 were further reported at 2017 [50, 635 
86]. Unfortunately, there was no genetic analysis to confirm these cases [86]. In 2019 a 636 
homozygous deletion of two nucleotides TG c.272-273del was reported in a Chinese 637 
family. The latter induced a frameshift mutation at codon 91 in exon 2 of the CISD2 638 
gene (Leu91fs) patient. This mutation was inherited from the parents who were first 639 
cousins [87].  640 
Since NAF-1 is localized to organelles involved in numerous metabolic and 641 
bioenergetics processes, i.e., mitochondria, ER and MAM, its absence impacts multiple 642 
cells, tissues and organs; mainly those with high metabolic and ATP demands [41, 88]. 643 
The latter lead to systemic abnormalities and manifestations including juvenile-onset 644 
insulin-dependent diabetes mellitus associated with pancreatic β-cell dysfunction 645 
which causes diabetes ‘Type 1-like’ pathophysiology [69]. WFS-T2 patients are 646 
however negative for anti-Glutamate dehydrogenase (anti-GAD that is the gold 647 
standard marker characteristic antibody of the autoimmune disease Type 1 Diabetes 648 
Mellitus) [89]. It was also shown that WFS-T2 patients do not suffer from diabetes 649 
insipidus, which is one of the WFS-T1 pathophysiological disorders [69]. Additionally, 650 
patients of WFS-T2 suffer from a progressive optic-nerve atrophy, sensorineural 651 
hearing loss and peptic ulcers disease [69]. Furthermore, WFS-T2 patients suffer from 652 
bleeding tendency characterized by abnormal platelet aggregation test against 653 
adenosine diphosphate (ADP), while this test was normal against collagen, restocetin 654 
and epinephrine [49, 75]. As they age, WFS-T2 patients suffer more often from 655 
neurological and psychiatric manifestations including anxiety, severe depression and 656 
psychosis [69, 70]. WFS-T2 patient typically die at a relatively early age, with median 657 
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age at death less than 30 years old (range, 24-45 years) [41, 70]. 658 
 659 
Fig. 7. The original CISD2 gene mutation (G109C) discovered as the causative agent of WFS-T2. 660 
A. A normal CISD2 gene is composed of three exons that transcribe the mature normal mRNA that 661 
translates into a normal NAF-1 protein. B. The point mutation (G109C) in exon 2 causing exon skipping, 662 
frameshift and premature stop codon that transcribe a much shorter mRNA that translates only 25% of 663 
NAF-1, the inter organelle domain (circled dashed blue line). C. mRNA length that is translated in normal 664 
human individual vs. the WFS-T2 patient cells. D. Western blot form normal fibroblasts vs. WFS-T2 665 
fibroblasts showing the complete absence of NAF-1 expression in this disease. 666 
 667 
IVd. In vivo mice model studies of NEET proteins 668 
 669 
Animal models are key to our understanding of the biology of different diseases, as well 670 
as for the testing of possible treatments [90]. In the past several years, mice models 671 
provided an excellent system for studying NEET proteins and their associated 672 
pathophysiological diseases [25]. Due to its association with the rare monogenic disease 673 
WFS-T2 and its potential involvement in aging (3), the CISD2 gene was an interesting 674 
target in different mice model systems. In 2009 Chen et al., were the first to report on 675 
generating a CISD2-/- knock out (KO) mice model system [25]. Their study revealed 676 
that CISD2-KO mice had a shortened life span compared to control, and that KO mice 677 
showed a premature aging phenotype, which correlates with the observation that the 678 
expression of NAF-1 is decreased with aging in wild type mice [25]. Other 679 
pathophysiological disorders observed in the CISD2-KO mice were prominent eyes, 680 
optic nerve degeneration resulting in blindness, protruding ears, early depigmentation 681 
and gray hair, hair follicle atrophy, and decreased density of hair follicles. In addition, 682 
the skin of CISD2-KO mice exhibits a hyperplastic epidermis, decrease in subcutaneous 683 
fat and muscle, and an increased thickness of the dermis layer. Furthermore, osteopenia 684 
resulting from thinner femur trabecular thickness, muscle degeneration and muscle 685 
atrophy caused by neuron degeneration were also observed [25, 35]. Diabetic features 686 
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of impaired glucose tolerance and decreased insulin levels were further observed in the 687 
CISD2-KO mice [25]. The phenotype of this mice model system resembled therefore 688 
the pathophysiology observed in WFS-T2 patients [25]. The same research group also 689 
established a second model system in which the CISD2 gene was overexpressed and 690 
demonstrated that overexpression of NAF-1 extended lifespan of mice, without any 691 
apparent side effects [26]. They showed that NAF-1 overexpression protects the 692 
mitochondria from age-associated damage and functional decline [26]. In addition to 693 
the obvious correction between age-associated reduction in whole-body energy 694 
metabolism, NAF-1 protein levels and mitochondrial function, their findings 695 
highlighted a new role for CISD2 in human longevity [26, 52]. In agreement with these 696 
phenotypic observations, the transcriptomics pattern of the CISD2-KO model 697 
resembled that of naturally aged mouse. Furthermore, increasing the expression level 698 
of NAF-1 delayed the aging progress of cardiac tissues and attenuated multiple age-699 
related structural defects and functions [55]. 700 
Another role for NAF-1, i.e., the maintenance of energy metabolism and glucose 701 
homeostasis, was established from an adipocyte-specific CISD2-KO mice model [30]. 702 
This model system revealed a role for NAF-1 in the development of epidermal white 703 
adipose tissue (eWAT) [30]. This study demonstrated that the function of eWAT 704 
adipocytes, that perform insulin-stimulated glucose uptake and adiponectin secretion, 705 
is impaired in the CISD2-KO model. It was hypothesized that adipogenesis is linked to 706 
the regulation of Ca2+ signaling by NAF-1, that is part of NAF-1 regulatory role as 707 
outlined above [30, 52]. To further investigate the role of mNT and NAF-1 in eWAT 708 
and skeletal muscle function, normal wild type mice were subjected to chronic exercise 709 
revealing that expression of both mNT and NAF-1 increased with exercise [91]. This 710 
exercise-induced adaptation was strongly correlated with mitochondrial protein 711 
expression and biogenesis, and with the increased expression of mNT and NAF-1, 712 
which may have an important role in maintaining the integrity of mitochondria [91]. 713 
Proper cardiac function was also shown to depend on NAF-1 expression [26], and the 714 
absence of NAF-1 in CISD2-KO mice is associated with intercalated disc defects due 715 
to mitochondrial degeneration, thereby impairing the electromechanical function of the 716 
heart [55]. This is thought to result from the disruption of Ca2+ hemostasis as explained 717 
above [46, 55]. The main Ca2+ regulatory role and the other cellular processes in which 718 
NAF-1 participates, e.g. different mitochondrial and ER functions, were further studied 719 
using embryonic cell lines obtained from a CISD2-KO mouse model or the transgenic 720 
model that over-expresses NAF-1 [55]. In this system it was shown that NAF-1 absence 721 
stimulated ER stress and increased the unfolded protein response process. Moreover, 722 
mouse embryonic fibroblasts (MEFs) were derived from the different NAF-1 models 723 
showing that Ca2+-regulation disturbances between the ER and the mitochondria 724 
(through the MAM) lead to disruptions in the glutathione cycle, and increased 725 
NAD+/NADH and ADP/ ATP ratios [28, 52]. 726 
In the Alzheimer’s disease (AD) mouse model JAX004462, NAF-1 protein levels 727 
were found to modulate the severity of certain AD phenotypes (e.g. acceleration of 728 
amyloid β-plaque formation) [38]. Overexpressing of NAF-1 promoted the survival and 729 
alleviates the pathophysiological defects in this AD model, through protecting against 730 
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amyloid β-mediated mitochondrial damage and preventing the loss of neurons and 731 
neuronal progenitor cells [38]. Moreover, NAF-1 overexpression reverted the 732 
expression AD-dysregulated genes (e.g. synapse-related functions, ion hemostasis and 733 
cell death) to normal levels [38]. This neuroprotective property of NAF-1 places it as a 734 
promising new target for AD treatment [54].  735 
Mouse models for mNT reveal that mNT overexpression enhanced lipid uptake and 736 
storage, leading to increased adiponectin levels that caused expansion of WAT mass, 737 
causing massive obesity as well as increased insulin sensitivity [23]. Significant 738 
reduction in inflammation and oxidative stress were also observed in the mNT 739 
overexpression models. In contrast, reduced mNT expression decreased mitochondrial 740 
respiratory capacity and decreased weight gain on a high fat diet. Different expression 741 
levels of mNT were therefore found to affect the dynamics of cellular and whole-body 742 
lipid hemostasis [23]. Expressing mNT in different mice tissues of the pancreas show 743 
the variability of mNT role in different tissues [27]. These findings further highlighted 744 
the interaction of mNT with Parkin that is proposed to modulate mitophagy [27, 92]. 745 
The expression of mNT either in α- or β- pancreatic cells identified a role for mNT in 746 
the control of glucose level and metabolism in mice [6, 19, 27].  747 
KO of mNT in CISD1-/- mice model was used to study how mNT expression levels 748 
affect chronic ethanol-fed mice. These studies showed a protective role for mNT in 749 
hepatic cells against alcoholic steatohepatitis [93]. These findings also suggested that 750 
mNT could be a therapeutic target [93]. In another CISD1(-/-) KO model of C57BL/6 751 
mice, an evaluation of pioglitazone-mediated neuroprotection was studied. It was found 752 
that in WT pioglitazone can protect against mitochondrial dysfunction, while in the KO 753 
model of mNT pioglitazone loses its neuroprotective effects. These findings 754 
highlighted mNT as an important regulator of Ca2+-mediated mitochondrial 755 
dysfunction in neurons that can be corrected by pioglitazone or other drugs targeting 756 
mNT [94]. 757 
Overexpression of mNT in HL1 cardiomyocytes cells isolated from a transgenic 758 
mouse, had a protective effect against oxidative stress induced by hydrogen peroxide 759 
[95, 96]. KO of CISD1 in mice, causes decrease in the oxidative phosphorylation 760 
capacity of the mitochondria [5]. When mNT was disrupted (KO) in diabetic Zucker 761 
rats, cardiac cells showed increased damage and oxidative stress, suggesting that mNT 762 
can be used as a pharmacological target for protecting cells after transplanting as they 763 
will be transitioning into an oxidative environment [96]. The loss of mNT results in 764 
mitochondrial dysfunction and loss of dopamine and tyrosine hydroxylase, with 765 
elevated ROS and reduced capacity to synthesize ATP. Reports of decreased 766 
performance of mNT KO model mice are consistent with the decrease in the level of 767 
dopamine in the striatum and and Parkinson’s disease-type motor defects [97]. 768 
  769 
V. NEET proteins support cellular proliferation and enhance oxidative 770 
stress tolerance of cancer cells 771 
 772 




As explained above, mitochondria are dynamic organelles able to adapt their structure 775 
and shape transitioning between fusion and fission based on the energetic and 776 
physiological needs of the cell. Mitochondria produce energy through oxidative 777 
phosphorylation (OXPHOS) and ATP production and are a major source of ROS that 778 
could cause oxidative damage to proteins, lipids, and DNA resulting in the development 779 
of cancer. The biology of mitochondrial support of tumorigenesis is considered at 780 
multiple stages. Tumor initiation, growth and survival can result from mutations in 781 
mitochondrial enzymes that induce cancer through mitochondrial signaling and 782 
oxidative stress. Redox homeostasis of the mitochondria can also regulate cell death 783 
through alterations in mitochondrial morphology and mitochondrial-associated 784 
signaling pathways. The survival of cancer cells can be promoted by alterations in 785 
mitochondrial mass by changes in the regulation of biogenesis and mitophagy. In 786 
addition, mitochondrial metabolic reprogramming, biogenesis, and redox homeostasis 787 
can contribute to the metastatic potential of cancer cells [98]. Mitochondrial dynamics 788 
of cancer cells can be linked to cancer development and progression, and has a strong 789 
impact on invasive and metastatic potential of cancer cells. Several publications 790 
demonstrated a link between mitochondrial dynamics and cancer [98]. Cancer cells and 791 
tumors can undergo a massive metabolic change, reducing the tricarboxylic acid (TCA) 792 
cycle and mitochondrial OXPHOS caused by mutations that affect TCA enzymes and 793 
the activity of the OXPHOS complexes leading to utilizing glycolysis as the main 794 
source for ATP production, also known as the Warburg effect [98]. It has been shown 795 
that cancer cells can use nutrients from host cells by inducing catabolic processes such 796 
as autophagy, mitophagy, aerobic glycolysis, and lipolysis [98, 99]. In addition to the 797 
Warburge effect, changes in nuclear and mitochondrial DNA expression, mutations and 798 
changes in the migartion protential of cells associated with mitochondrial dysfunction 799 
can induce cancer cell development, growth and metastasis [98]. Changes and 800 
imbalances in mitochondrial dynamics, such as changes in regulated degradation 801 
processes, can cause an alteration in the homeostasis of cells that can induce tumor 802 
inititiation, growth, and mestastsis, suggesting an important role for mitochondrial 803 
dymanics, autophagy, and mitophagy in cancer deveolopment. Autophagy can either 804 
support cancer cell survival or promote cancer cell death, depending on its cellular 805 
context, while mitophagy dysfunction can induce cancer development [98]. 806 
Accumulation of damaged mitochondria caused by a decrease in mitophagy can lead to 807 
an increase in oxidative damage and to a disrupt redox balance, causing ROS-induced 808 
DNA mutations and genetic instability [99]. OMM proteins play a major role in 809 
promoting cancer cell progression, VDAC1 is important for the metabolic phenotype 810 
of cancer cells; it regulats mitochondrial activity and glucose metabolism. Moreover, 811 
VDAC1 can directly bind to hexokinase II (HK II), and induce its activity. HK 812 
expression is upregulated in multiple cancer types and this enzyme catalyzes the first 813 
reaction of glycolysis that sustains the elevated rates of glucose catabolism leading to 814 
increased tumor growth [100]. The interaction between VDAC1 and HK II inhibits 815 
mitochondria-induced apoptosis, helping tumor cells to increase survival and growth. 816 
VDAC1 is also a mitochondrial target of Parkin, required for its efficient targeting of 817 
damaged mitochondria and mitophagy [101], demonstrating that, in addition to fusion 818 
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and fission proteins, OMM proteins also have an important role linking mitochondrial 819 
dynamics with cancer development. 820 
 821 
Vb. The role of NEET protiens in cancer 822 
 823 
NEET proteins were shown to have an important role in cancer, promoting 824 
proliferation and survival of cancer cells, and inducing cancer cell metastasis and tumor 825 
growth [12]. Recent studies indicated that mNT regulates the channel function of 826 
VDAC1 and that this interaction is dependent on the redox state of the [2Fe–2S] clusters 827 
of mNT [17]. Analysis of mNT expression using the human atlas tool 828 
(https://www.proteinatlas.org/ENSG00000122873-CISD1/pathology) strongly 829 
suggests that mNT could be used as a prognostic marker for breast, liver and urothelial 830 
cancer (unfavorable) all with p < 0.001, demonstrating that cancer patients displaying 831 
high expression levels of CISD1 have a lower survival rate. Interestingly, most of the 832 
published work in the field of NEET protein family and cancer focused on NAF-1, 833 
although recently in our hands (personal communication), we also find a strong role for 834 
mNT in cancer. 835 
A study of Pancreatic cancer demonstarted that high levels of NAF-1 are associated 836 
with advanced clinical stage, increased tumor size and increased metastasis. In addition, 837 
multivariate analysis suggests that NAF-1 is an independent prognostic marker for 838 
pancreatic cancer. NAF-1 silencing in pancreatic cell line showed an inhibition of 839 
survival and growth of these cells and inactivation of the Wnt, β-catenin pathway. NAF-840 
1 silencing inhibited the epithelial-to-mesenchymal transition (EMT) through the 841 
Wnt/β-catenin pathway and suppressed the tumorigenesis of pancreatic cancer cells, 842 
suggesting that NAF-1 and the Wnt/β-catenin pathway contribute to the proliferation 843 
of pancreatic cancer [102]. A study on Gastric cancer (GC) found that NAF-1 was 844 
upregulated in gastric cancer cells and is a prognostic factor for poorer survival of 845 
gasrtic cancer patiens. High expression level of NAF-1 was correlated with clinical 846 
stage and metastasis of GC. Overexpressing NAF-1 promoted the proliferation of 847 
gastric cancer cells, while silencing NAF-1 inhibited tumor growth in vivo. 848 
Downregulation of cyclin-dependent kinase inhibitor p21Cip1 and p27Kip1, and 849 
activation of AKT signaling were found to be associated to NAF-1 effect on induced 850 
proliferation of gastric cells [103]. An additional study on GC showed that NAF-1 851 
enhanced sensitivity to 5-fluorouracil (5-FU) through an increase in apoptosis and 852 
inhibition of protective autophagy through the activation of the AKT/mTOR pathway 853 
[104]. In a more recent study on prostate cancer [105] phloretin treatment increased 854 
oxidative stress, as demonstrated through lower antioxidant enzymes. This study also 855 
found that increased ROS significantly downregulated multiple components of the 856 
Wnt/β-catenin signaling pathway, suggesting that phloretin anticancer activity could 857 
occur through generating ROS to influence Wnt/β-catenin signaling that is regulated by 858 
NAF-1. A study aimed at investigating the expression pattern and clinicopathological 859 
significance of NAF-1 in patients with hepatocellular carcinoma (HCC) found that 860 
NAF-1 expression in liver cancer cell lines and tissues was significantly up-regulated 861 
at both the RNA and protein levels. NAF-1 was found as an independent marker for 862 
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poor prognosis of liver cancer [12, 106]. HCC patients with high NAF-1 expression 863 
displayed a shorter survival and a higher recurrence rate than those with low expression. 864 
In addition, down regulation of NAF-1 in hepatoma cells suppressed cell proliferation 865 
in vitro and inhibited tumor size in vivo. This study concluded that NAF-1 may serve 866 
as a prognostic marker and a novel therapeutic target for HCC, as well as that NAF-1 867 
plays an important role in promoting proliferation and enhanced progression of HCC. 868 
A study of patients with early-stage cervical cancer [12, 107] found that CISD2 869 
expression was significantly upregulated in cervical cancer cells at the mRNA and 870 
protein levels. Statistical analysis showed a significant correlation between CISD2 871 
expression and the expression of squamous cell carcinoma antigen, myometrium 872 
invasion, recurrence, lympho-vascular space involvement and especially pelvic lymph 873 
node metastasis. Patients with higher NAF-1 expression had shorter overall survival 874 
rate than patients with lower NAF-1 expression.  875 
Multivariate analysis also suggested that NAF-1 expression may be a prognostic 876 
indicator for the survival of patients with early-stage cervical cancer and suggested that 877 
NAF-1 may serve as a novel biomarker for early-stage cervical cancer progression. In 878 
laryngeal squamous cell carcinoma (LSCC), NAF-1 was found to be up-regulated in 879 
LSCC tissues compared with adjacent noncancerous tissues both at mRNA and protein 880 
levels. NAF-1 was significantly correlated with T stage, lymph node metastasis, clinical 881 
stage and disease progression [108]. 882 
NAF-1 is thought to support mitochondrial iron and ROS metabolism, promoting 883 
cancer cell survival via stabilization of HIF1α and suppression of apoptosis. It was 884 
shown that increased uptake of iron into cells and mitochondria causes a metabolic shift 885 
that enhances oxygenic glycolysis, and the activation of cellular stress pathways 886 
associated with HIF1α stabilization and mTOR inactivation have been demonstrated to 887 
result from suppression of NAF-1 in breast cancer cells [5, 34]. The role of NAF-1 in 888 
promoting cancer cell proliferation studied by Darash-Yahana et al., [73] showed that 889 
overexpression of NAF-1 in xenograft tumors resulted in a dramatic increase in tumor 890 
size and aggressiveness. Breast cancer cells with enhanced expression of NAF-1 were 891 
more tolerant to oxidative stress and undergo less apoptosis and autophagy. The degree 892 
of lability of the NAF-1 [2Fe–2S] cluster was found to be critical for NAF-1 function 893 
in cancer cells. A mutated form of NAF-1 with a single point mutation (H114C), which 894 
stabilizes the NAF-1 cluster, resulted in a dramatic decrease in tumor size, enhanced 895 
mitochondrial iron and ROS accumulation, and reduced cellular tolerance to oxidative 896 
stress. Breast cancer cells treated with pioglitazone revealed a similar effect on 897 
mitochondrial iron and ROS accumulation, demonstrating for the first time that the 898 
cluster of NAF-1 is critical for its function in cancer cells. This study suggests that 899 
drugs that target the lability or stability of NAF-1 and mNT [2Fe-2S] clusters could be 900 
used as a theraputic approach for patients with tumors that display high expression level 901 
of NAF-1 [73].  902 
In addition to mNT and NAF-1, knockdown of MiNT also leads to increased 903 
accumulation of mitochondrial labile iron, as well as increased mitochondrial reactive 904 
oxygen production [10]. The MiNT protein could therefore function in the same 905 
pathway as its homodimeric counterparts (mNT and NAF-1), and could be a key player 906 
25 
 
in this pathway within the mitochondria. As such, it represents an additional NEET 907 
target for anticancer or antidiabetic drug development. 908 
Through their effect on mitochondrial function and dynamics, NEET proteins could 909 
therefore impact cancer growth, development and metastasis (Fig. 8). 910 
 911 
Fig. 8. Mitochondrial dynamics can impact tumor growth and/or metastasis of cancer cells through 912 
cluster transfer reactions involving NEET proteins. Mitochondrial fusion promotes oxidative 913 
phosphorylation (OXPHOS) at the expense of anaerobic glycolysis, leading to increased ROS tolerance 914 
that will inhibit migration of cancer cells but may increase tumor growth. On the other hand, 915 
mitochondrial fission inhibits oxidative metabolism by increasing the energetic yield of glycolysis, 916 
easing the process of metastasis. Based on our published data [73] we found that high expression levels 917 
of NAF-1 increases tumor growth, oxidative phosphorylation and ROS resisitance. We also showed that 918 
knockdown of NEET proteins causes decreased OXPHOS while increasing ROS and Fe accumulation 919 
in the mitochondria [5, 10, 34]. The fine balance between tumor growth and tumor metastasis, critical 920 
for the fate of cancer cells, needs to be further studied in relation to NEET expression and mitochondrial 921 
dynamics in cancer cells, and the potential use of different NEET-targeting drugs to treat cancer should 922 
be further evaluated. 923 
 924 
VI. NEET proteins as drug targets 925 
The expression level of NEET proteins, as detailed above, is correlated with the 926 
development of many different diseases (e.g., cancer, neurodegeneration, metabolic 927 
diseases and genetic disorder such as WFS-T2). In cancer, the expression of NEET 928 
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proteins is significantly increased supporting the proliferation of cancer cells by 929 
maintaining mitochondrial homeostasis (described above [5, 12]). In contrast, reduced 930 
or lack of expression of NEET proteins leads to early senescence and the development 931 
of neurodegeneration and metabolic diseases [25, 27, 97]. Disrupting the lability of 932 
NEET clusters was found to play an important role for the development of cancer [73], 933 
and can be also involved in many other mitochondria-associated diseases. Hence, 934 
NEET proteins represent novel and highly promising targets for drug design. As 935 
mentioned above, NEET proteins were discovered through their binding of the 936 
thiazolidinedione (TZD) drug, pioglitazone (PGZ, see Fig. 9), used as a treatment for 937 
types 2 diabetes [6]. TZD binding to NEET proteins stabilizes their [2Fe–2S] clusters 938 
and increases mitochondrial labile iron and ROS levels in cancer cell [73]. Such 939 
stabilization in turn inhibits the ability of NEET proteins to transfer their [2Fe–2S] 940 
clusters to different apo-acceptor proteins. This leads to the blocking of cluster 941 
mobilization from the mitochondria to the cytosol and to impaired mitochondrial iron 942 
and ROS homeostasis [5, 73]. Accordingly, a His to Cys mutation of the histidine ligand 943 
of NAF-1 [2Fe–2S] cluster (H114C) leads to a 25-fold increase in cluster stability and 944 
to the inhibition of H114C cluster transfer abilities to apo-acceptor proteins [5, 73]. The 945 
overexpression of this mutated form of NAF-1 in breast cancer cells revealed that in 946 
H114C cells, the levels of mitochondrial iron and ROS were significantly increased, 947 
and the tolerance to oxidative stress was drastically decreased [73]. The stabilization of 948 
the [2Fe–2S] further reduced cancer cell proliferation and tumor growth [73]. These 949 
findings are similar to those of PGZ binding to NEET proteins, suggesting that in cancer 950 
cells, modulating NEET protein cluster stability by different drugs could suppress 951 
cancer cell proliferation [73]. This can be achieved by designing of ligands to the cluster 952 
[5, 12, 73]. Several ligands were indeed shown to have an effect on the stability of the 953 
NEET cluster. They could present a promising potential for therapeutic use, not only 954 
for cancer but also for neurodegenerative and metabolic diseases such as diabetes [109]. 955 
While the stabilization of the NEET [2Fe–2S] cluster impacts mitochondrial 956 
homeostasis, some compounds were found to destabilize the NEET [2Fe–2S] cluster 957 
[12]. Destabilization of the [2Fe–2S] cluster in cancer cells induced alterations in 958 
mitochondrial homeostasis (e.g. respiration) and decreased cell proliferation similar to 959 
what was found with reduced NEET proteins expression [12]. To date, despite the 960 
critical role that NEET proteins play in many human diseases, only few efforts were 961 
directed at the development of new ligand and drugs that target these proteins [5, 73, 962 
83, 109].  963 
NEET ligands identified so far range from synthetic molecules to natural 964 
compounds and their derivatives. The former are mostly TZD derivatives such as the 965 
cluster stabilizer PGZ [5]. The binding pose of several of these ligands onto mNT was 966 
obtained so far via molecular docking. While docking may be a rather approximate for 967 
proteins containing a transition metal cluster [110], very important insights could be 968 
achieved already with this simple approach. Indeed, subsequent structure-activity 969 
relationship studies [111, 112] showed that the binding affinity of TZD-type ligands to 970 
NEET proteins is largely dependent on the aromatic moiety (e.g. phenol group) in these 971 
molecules. Modifications of the nitrogen atom on the TZD ring with an acidic group is 972 
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also beneficial for increasing its binding affinity to mNT. Changing the TZD ring into 973 
a TTD (2-thioxothiazolidin-4-one) ring can also cause a relative potency improvement. 974 
These findings provided an important reference for enhancing the affinity of TZD-type 975 
ligands and reducing side effects. Due to the lack of the PPAR-γ binding region, NL-1 976 
pharmacological effects acts primarily through NEET proteins interaction [94]. Using 977 
nanotechnology to encapsulate, NL-1, into poly (lactic-co-glycolic acid) nanoparticles 978 
can further overcome low solubility of the molecule and enable it to cross the brain 979 
blood barriers (BBB) [113]. These strategies laid the basis for the research and 980 
development of drugs targeting NEET proteins [83, 113]. Takahashi et al. [109] 981 
designed and synthesized a PGZ derivative, named TT01001 that interacts with mNT 982 
specifically without interacting with PPAR-γ, originally targeted by PGZ [6]. In 983 
addition to other TZD-like ligands, diuretic furosemide (see Fig. 9) was also shown to 984 
bind to mNT and stabilize its [2Fe–2S] cluster. The first furosemide-mNT co-crystal 985 
structure recently confirmed that furosemide binds to the junction between the NEET 986 
protein [2Fe–2S] cluster-binding domain and the β-cap domain [83]. This structure laid 987 
a critical molecular structural foundation for further development of rational stabilizer 988 
designs targeting NEET protein by the “cluster stabilizer mechanism”. 989 
NEET protein ligands of natural products were primarily determined by molecular 990 
docking and experimental screening, and include chromen-4-one compounds with 991 
symmetrical chemical scaffold, such as magnolol, curcumin, cromolyn, enterobactin 992 
and others [111]. Although many natural product ligands have similar, or better, 993 
theoretical calculation binding affinity compared to PGZ, many of them were not 994 
identified as stabilizers or destabilizers of the [2Fe–2S] cluster. Nevertheless, the 995 
unique chemical framework of natural products expands the ligand design ideas [12], 996 
and include studies of the molecular interactions of the Garcinia xanthone derivative, 997 
cluvenone (CLV, stabilizer) and its derivatives MAD-28 (destabilizer) and MAD-44 998 
(stabilizer, see Fig. 9) with mNT and NAF-1. Within the limitations of the methodology 999 
reported above, the MAD-28 ligand was suggested to form an additional hydrogen bond 1000 
with Cys83 of mNT, which causes energy penalty and deflects the coordination of the 1001 
iron-sulfur cluster-ligated His, increasing the coordination bond length, thereby 1002 
accelerating the release of the iron-sulfur cluster [114]. 1003 
With very few exceptions, the mechanism by which NEET ligands exerts a 1004 
stabilizing or destabilizing effect is not yet known. Most reported ligands are stabilizers 1005 
[12, 83, 109]. Identifying destabilizers is therefore very important from a 1006 
pharmacological perspective. Indeed, in diseases like cancer a stabilizer may perform 1007 
well but in other diseases (such as WFS-T2) a destabilizer may provide the solution 1008 
(personal communication). A more refined understanding and drug control of NEET 1009 
protein function, as well as better delivery tools, may therefore be required for utilizing 1010 




Fig. 9. The stabilization and destabilization effects of different NEET protein ligands. Known 1013 
destabilizing drugs are shown on left and known stabilizing drugs are shown on right. 1014 
 1015 
 1016 
VII. Other organisms in which NEET protein structure and function 1017 
were studied 1018 
 1019 
VIIa. NEET proteins and programmed cell death in C. elegans 1020 
 1021 
The programmed cell death (PCD) pathway is a tightly regulated pathway, key to the 1022 
survival and development of almost all multicellular organisms. The core mammalian 1023 
PCD pathway is regulated by the pro-survival Bcl-2 protein, as well as by the pro-death 1024 
APAF-1 and caspase proteins. One pathway of regulation specifically involves 1025 
interactions between pro-survival Bcl-2 proteins and pro-death Bcl-2 homology region 1026 
3 (BH3) domain-containing proteins, highlighting the BH3 domain as a pro- or anti-1027 
apoptotic modulating domain of Bcl-2 activity. Several studies have implicated NEET 1028 
proteins as involved in the regulation of PCD or apoptosis via BH3-associated 1029 
interactions with Bcl-2. Crosslinking followed by mass spectrometry identified NAF-1 1030 
as a protein that binds to the pro-survival Bcl-2 protein at the ER. The displacement of 1031 
NAF-1 from Bcl-2 binding, thought to occur through the ER localized BH3-only 1032 
protein Bik, lead to the hypothesis that in mammalian cells, a Bcl-2-NAF-1 complex at 1033 
the ER has a role in the regulation of apoptosis and autophagy [5]. Further 1034 
investigations of this interaction via binding interface mapping between Bcl-2 and 1035 
NAF-1 discovered that NAF-1 binds to Bcl-2 at a BH3-only binding site, providing 1036 
structural justification for the displacement of Bik by NAF-1 [5]. Additional support 1037 
for NAF-1 involvement in the regulation of autophagy and apoptosis comes from 1038 
studies utilizing cancer cell lines and xenograft tumors with altered NAF-1 expression 1039 
in mice. In these studies, NAF-1 suppression, or altered function, resulted in the 1040 
activation of apoptosis [5, 73]. These studies further linked NAF-1 with the regulation 1041 
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of apoptosis, however they did not identify the different proteins and genes involved in 1042 
this process.  1043 
Recent genetic and molecular studies conducted in the model system 1044 
Caenorhabditis elegans, discovered that the CISD gene family regulates germline 1045 
apoptosis. Thus, in the absence of NEET protein function apoptosis of germline cells 1046 
was enhanced and abnormalities occurred in C. elegans reproduction. This process was 1047 
shown to be dependent on the core apoptotic machinery of C. elegans since disruptions 1048 
in core apoptotic machinery genes such as deletions of ced-3/caspase or ced-4/APAF-1049 
1, or gain-of-function of ced-9(n1950)/Bcl-2 reduced the number of germline cell 1050 
corpses in CISD1 null animals. Furthermore, disruption of the pro-apoptotic BH3 1051 
protein, CED-13, significantly reduced the number of germ cell corpses observed in 1052 
cisd dysfunctional animals. These findings support a model in which CISD proteins 1053 
function as anti-apoptotic proteins that regulate PCD in the C. elegans germline by 1054 
competing with the pro-apoptotic protein CED-13 for the binding of Bcl-2 [13]. NEET 1055 
proteins could therefore perform a pro-survival/anti-apoptotic function through 1056 
inhibiting CED-9 (Bcl-2) at the CED-13 (BH3 domain) interaction site, preventing 1057 
CED-9(Bcl-2)-CED-13 interaction that induces PCD and promoting germ cell survival 1058 
[13]. The in vivo studies in C. elegans described above supported previous 1059 
computational and in vitro experimental analysis of NAF-1-Bcl-2 binding that further 1060 
dissected the binding interface between these two proteins and revealed that it was 1061 
mediated through the Bcl-2 BH3-binding domain [114].  1062 
The C. elegans studies described above, as well as work by others [115] further 1063 
demonstrated that knocking out NEET proteins in C. elegans results in a dramatic effect 1064 
on metabolic processes, as well as on mitochondrial morphology, and that these 1065 
processes were found to occur under high levels of ROS and low levels of ATP [115]. 1066 
 1067 
VIIb. NEET proteins in Plants 1068 
 1069 
 Arabidopsis thaliana contains a single gene encoding a NEET protein (At5g51720, 1070 
named AtNEET) that shows 50 and 57% similarity to the mammalian NEET proteins 1071 
mNT and NAF-1, respectively, and displays biochemical, biophysical, and structural 1072 
characteristics common to those of other NEET proteins [11]. Similar to mNT and 1073 
NAF-1, the plant protein contains a typical NEET fold with a strand-swapped β-cap 1074 
domain and a cluster binding domain [11]. Expressing AtNEET-GFP fusion protein in 1075 
Arabidopsis plants indicated that the AtNEET protein is localized to chloroplasts and 1076 
mitochondria [11] and its expression is restricted to leaves [116]. The complete absence 1077 
of AtNEET from any of the mutant collections currently available suggests that this 1078 
protein could be essential for plants. Knockdown and RNA interference (RNAi) lines 1079 
with suppressed expression of AtNEET showed a late bolting and early senescence 1080 
phenotype and accumulated higher levels of Fe and ROS, indicating that AtNEET could 1081 
play a key role in maintaining Fe and ROS homeostasis in Arabidopsis plants [11].  1082 
One of the suggested functions of NEET proteins in different biological systems is 1083 
that of [2Fe–2S] cluster transfer [2]. Indeed, mimicking the function of the mammalian 1084 
NEET protein mNT in human cells, AtNEET was shown to transfer its [2Fe–2S] 1085 
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clusters to apo-Ferredoxin (FD) and mitochondria [11], as well as to the cytosolic [2Fe–1086 
2S] protein DRE2 [14], further supporting the involvement of AtNEET in Fe 1087 
metabolism in plants (Fig. 10). In addition, growth of AtNEET knockdown seedlings 1088 
was previously shown to be insensitive to high Fe levels, but sensitive to low levels of 1089 
Fe [11], suggesting a role for AtNEET in Fe transfer, distribution, and/or management 1090 
in plant cells. 1091 
 1092 
Fig. 10. Model showing the putative role of AtNEET in the mobilization of [2Fe–2S] clusters from 1093 
the chloroplastic Fe–S biogenesis machinery to chloroplastic and cytosolic Fe–S proteins. A 1094 
disruption in the function of AtNEET via expression of the dominant-negative AtNEET variant H89C 1095 
blocks the mobilization of some [2Fe–2S] clusters within and outside of the chloroplast, and triggers 1096 
over-accumulation of Fe in the chloroplast that enhances ROS accumulation, resulting in chlorosis, 1097 
structural damage to chloroplasts and a high seedling mortality rate. Representative images of wild type 1098 
AtNEET (top) and AtNEET-H89C (bottom) seedlings and chloroplasts are shown (After [14]). 1099 
 1100 
Because chloroplasts and mitochondria contain many Fe-S proteins and require a 1101 
supply of Fe from the cytosol for the biogenesis of Fe–S cluster proteins, the 1102 
localization of AtNEET to these subcellular compartments [11] could be central to the 1103 
proposed role of this protein in Fe–S cluster transfer. To shed light on the function of 1104 
AtNEET in relation to its localization, a dominant-negative strategy [73] in which a 1105 
mutated form of AtNEET (H89C) that is unable to donate its cluster to an acceptor 1106 
protein, was recently used (Fig. 10) [14]. Disrupting AtNEET function by using this 1107 
strategy resulted in transcriptional re-programming of several networks mediating ROS 1108 
metabolism, Fe–S biogenesis and Fe– deficiency responses, as well as in a decrease in 1109 
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the level of key Fe–S proteins, such as FD, and an over-accumulation of Fe at the whole 1110 
plant level, and in particular in chloroplasts [14]. These changes were accompanied by 1111 
chlorosis, severe structural damage to chloroplasts and a high mortality rate of seedlings. 1112 
In addition, the disruption in AtNEET function blocked the transfer of Fe–S clusters 1113 
from the chloroplastic [2Fe–2S] biogenesis machinery to chloroplastic (FD1) and 1114 
cytosolic (DRE2) [2Fe–2S] proteins, suggesting that AtNEET could function in 1115 
mobilizing clusters from the chloroplastic [2Fe–2S] biogenesis pathway to target 1116 
proteins such as FD1 and DRE2 [14]. Similar to animal cells [5, 11, 12], AtNEET could 1117 
be localized inside the chloroplast, as well as on its outer membrane (and at the 1118 
mitochondria), implicating AtNEET in mediating [2Fe–2S] cluster transfer between 1119 
these different subcellular compartments and the cytosol [14]. The conserved role for 1120 
NEET proteins in Fe–S metabolism/Fe homeostasis between different organisms and 1121 
kingdoms could therefore highlight an ancient function as well as a central role for these 1122 
Fe–S proteins in linking organelle and cytosol homeostasis and function. 1123 
 1124 
VIII. Summary 1125 
 1126 
Since the discovery of NEET proteins in 2004, many advances were made in their 1127 
structural and functional characterization. A key role for NEET proteins was identified 1128 
in numerous human pathologies including cancer, diabetes, neurodegenerative diseases 1129 
such as Alzheimer and Parkinson’s, obesity and heart disease. At the cellular level, 1130 
NEET proteins were found to be involved in the regulation of autophagy, apoptosis, 1131 
ferroptosis, ROS production, tolerance and signaling, calcium signaling, cell 1132 
proliferation, electron transfer reactions, redox control and iron and iron-sulfur 1133 
homeostasis. Key interactions between NEET proteins and central regulators such as 1134 
VDAC and Bcl-2 were also identified.  1135 
We believe that the future of NEET protein research will greatly benefit from 1136 
addressing the following research avenues: 1137 
 1138 
• Determining the mechanisms and outcomes of NEET protein involvement in 1139 
the regulation of mitochondrial dynamics and morphology. 1140 
• Revealing and studying the scope of signaling networks, and protein-protein 1141 
interactions, impacted by NEET proteins in different cells and tissues.  1142 
• Developing drugs with high specificity and efficacy in treating the different 1143 
diseases NEET proteins are associated with. A special effort should be directed 1144 
at the development of novel drugs that can alter the lability of NEET [2Fe–2S] 1145 
clusters, as a particularly exciting venue of research.  1146 
• Fostering research on plants, which appear to contain a single member of the 1147 
NEET protein family that could be used in the production of crops with high 1148 
tolerance to different stress conditions. 1149 
Although these research avenues are highly challenging, their potential benefits could 1150 
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